|
Key elements to successful translational drug development
-
Close collaboration between clinicians and basic scientists
-
Access to the top minds in the multiple myeloma field
-
Good communication of discoveries and advances in the field
-
High-quality multiple myeloma research samples and reagents
-
On-going training of the next generation of myeloma researchers and clinicians
|
The team at UCSF has built the Grand MMTI organization to facilitate successful translational drug development by:
-
Providing seed funding to UCSF researchers to foster pioneering research in multiple myeloma
-
Providing funding to support innovative multiple myeloma clinical trials
-
Providing funding to support training of clinical fellows in multiple myeloma
-
Meeting monthly to provide updates on programs and share ideas
-
Maintaining an expanding tissue bank and database that offers important samples to Grand MMTI researchers, as well as industry collaborators
-
Establishing a world class scientific advisory board composed of leading multiple myeloma experts
-
Fostering collaborations with other multiple myeloma groups to exploit synergies.
The research carried out by the Grand MMTI team is focused in a number of areas known to be important in multiple myeloma disease and treatment:
-
Apoptotic pathways
-
Unfolded Protein Response
-
Kinase signaling pathways
-
Ubiquitin proteasome system
-
Biomarkers
As the Grand MMTI program grows, additional targets will be evaluated and, when appropriate, advanced as targets for novel therapeutic development.
